Recently, a similar strategy using a fusion of Her2 antibody and protamine loaded with Plk1 siRNAs was shown to suppress proliferation of Her2 positive breast cancer cells and primary human cancers in orthotropic breast cancer models [105]. Here, ERBB2 is linked to cancer.